Literature DB >> 2141212

Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma.

S Gröndal1, B Eriksson, L Hagenäs, S Werner, T Curstedt.   

Abstract

The urinary steroid profile was determined in 24 patients with adrenocortical carcinoma. Seventeen of the patients had Cushing's syndrome, virilization or feminization, and 7 had no signs of endocrine disease. Seven of the 11 patients still alive are free of disease, after a follow-up period of 5-75 months. The steroid profile varied widely between the patients with adrenocortical carcinoma. Patients with Cushing's syndrome had increased levels of cortisol metabolites and those with virilism had raised excretion of androgen metabolites. Six of the patients with adrenocortical carcinoma showed normal values of these metabolites. In 23 of the 24 patients the excretion of 3 beta-hydroxy-5-ene steroids and/or metabolites of cortisol precursors, such as tetrahydro-11-deoxycortisol, were significantly increased, compared with healthy controls or patients with adrenal adenomas. These findings suggest a relative deficit or low activity of 3 beta-hydroxysteroid dehydrogenase/delta isomerase and/or 11 beta-hydroxylase in tumour tissue. In the single patient where the steroid profile failed to indicate malignancy, hypercortisolism was seen and the tumour mass was small. The steroid excretion normalized after radical surgery and decreased in patients responding to chemotherapy. During recurred disease the metabolites of 3 beta-hydroxy-5-ene steroids and/or cortisol precursors increased, but in some patients the excretory pattern then was different from that seen before treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141212     DOI: 10.1530/acta.0.1220656

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  17 in total

1.  Monoclonal Antibodies Recognizing Normal and Neoplastic Human Adrenal Cortex.

Authors:  Carin Backlin; Claes Juhlin; Lars Grimelius; Kristina Wiberg; Per Heilman; Goran Akerstrom; Jonas Rastad
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 2.  5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Authors:  Sarika N Rao; Mouhammed Amir Habra
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

3.  Exploiting the Unusual to Find the Rare: Novel Steroid Metabolites Pinpoint Adrenal Cancer Patients.

Authors:  Tobias Else; Richard J Auchus; William E Rainey
Journal:  Horm Cancer       Date:  2015-06-12       Impact factor: 3.869

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

5.  Structure elucidation of the diagnostic product ion at m/z 97 derived from androst-4-en-3-one-based steroids by ESI-CID and IRMPD spectroscopy.

Authors:  Mario Thevis; Simon Beuck; Sebastian Höppner; Andreas Thomas; Joseph Held; Mathias Schäfer; Jos Oomens; Wilhelm Schänzer
Journal:  J Am Soc Mass Spectrom       Date:  2011-12-16       Impact factor: 3.109

6.  An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence?

Authors:  H Falhammar; M Thorén
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 7.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

8.  Dexamethasone-suppressible feminizing adrenal adenoma.

Authors:  M Paja; S Díez; T Lucas; A Ojeda; L Salto; J Estrada
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

9.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

10.  Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.

Authors:  Tanweera S Khan; Anders Sundin; Claes Juhlin; Erik Wilander; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.